JAM3 and allergic contact dermatitis: Consistent with this observation, other investigators found no difference regarding the number of circulating lymphocytes between anti-JAM-C-treated and isotype control-treated groups in a model of allergic contact dermatitis responsive to anti-JAM-C administration [12].